A detailed history of Allworth Financial LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 82 shares of SRPT stock, worth $8,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82
Previous 65 26.15%
Holding current value
$8,572
Previous $10,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$124.33 - $156.75 $2,113 - $2,664
17 Added 26.15%
82 $10,000
Q2 2024

Jul 23, 2024

BUY
$113.33 - $163.85 $2,606 - $3,768
23 Added 54.76%
65 $10,000
Q1 2024

Apr 25, 2024

SELL
$93.7 - $141.53 $4,497 - $6,793
-48 Reduced 53.33%
42 $5,000
Q4 2023

Jan 24, 2024

BUY
$67.31 - $124.76 $605 - $1,122
9 Added 11.11%
90 $8,000
Q3 2023

Oct 31, 2023

BUY
$102.5 - $123.59 $4,612 - $5,561
45 Added 125.0%
81 $9,000
Q2 2023

Jul 18, 2023

SELL
$106.4 - $157.19 $851 - $1,257
-8 Reduced 18.18%
36 $4,000
Q1 2023

Apr 18, 2023

BUY
$117.53 - $155.99 $1,998 - $2,651
17 Added 62.96%
44 $6,000
Q4 2022

Jan 13, 2023

SELL
$100.86 - $132.13 $302 - $396
-3 Reduced 10.0%
27 $0
Q3 2022

Oct 18, 2022

BUY
$75.71 - $119.24 $1,817 - $2,861
24 Added 400.0%
30 $3,000
Q2 2022

Jul 13, 2022

SELL
$62.69 - $88.44 $10,343 - $14,592
-165 Reduced 96.49%
6 $0
Q1 2022

Apr 22, 2022

BUY
$63.15 - $90.42 $10,798 - $15,461
171 New
171 $13,000
Q4 2021

Jan 21, 2022

SELL
$77.28 - $99.42 $48,995 - $63,032
-634 Closed
0 $0
Q3 2021

Nov 02, 2021

BUY
$65.97 - $92.48 $8,905 - $12,484
135 Added 27.05%
634 $59,000
Q2 2021

Aug 02, 2021

SELL
$69.38 - $86.75 $13,876 - $17,350
-200 Reduced 28.61%
499 $39,000
Q3 2017

Oct 12, 2017

BUY
$35.73 - $47.15 $10,718 - $14,145
300 Added 75.19%
699 $32,000
Q2 2017

Aug 07, 2017

BUY
N/A
399
399 $13,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.